Angiogenesis
Angiogenesis is the formation and remodelling of new blood vessels and capillaries from growth of pre-existing blood vessels. It normally occurs during wound healing and embryonic development, but is also required for tumour growth and metastasis in cancer.
-
PF-2341066 (Crizotinib)
Catalog No. A10712 ALK/ c-Met 抑制剂PF-2341066 (Crizotinib)是c-Met激酶和NPM-ALK的抑制剂。PF-2341066抑制ALK阳性ALCL细胞中的细胞增殖(IC50 = 30 nM)。 了解更多 -
EW-7197 (Vactosertib)
Catalog No. A14213 ALK4/ALK5 抑制剂EW-7197是一种高效,选择性可生物利用的TGF-βI受体ALK4/ALK5抑制剂,IC50分别为13 nM和11 nM。 了解更多 -
GSK1838705A
Catalog No. A11175 IGF-1R 抑制剂GSK1838705A是一种小分子激酶抑制剂,其抑制IGF-IR和胰岛素受体的IC50分别为2.0和1.6 nmol/L。 了解更多 -
Crizotinib hydrochloride
Catalog No. A16245 c-Met/NPM-ALK 抑制剂Crizotinib hydrochloride是c-Met激酶和NPM-ALK的抑制剂。 了解更多 -
ASP3026
Catalog No. A11773 -
ALK-IN-1 (Brigatinib analog, AP26113 analog)
Catalog No. A11948 ALK 抑制剂AP26113是一种有效的,选择性的ALK抑制剂,对野生型的功效为0.62 nM,对包括crizotinib耐药的L1196M系在内的多种突变体的活性也很强。在一组EML4-ALK或NPM-ALK阳性细胞系中,AP26113的IC50值为4-31 nM。 了解更多 -
CEP-28122
Catalog No. A13744 -
PF-06463922
Catalog No. A14207 ALK 抑制剂PF-06463922是一种有效的双重ALK/ROS1抑制剂,对ROS1,ALK(WT)和ALK(L1196M)的Ki分别为<0.02 nM,<0.07 nM和0.7 nM。 了解更多 -
WZ4003
Catalog No. A14312 -
A 77-01
Catalog No. A14436 -
LDK378 (Ceritinib) dihydrochloride
Catalog No. A15142 ALK 抑制剂LDK378 (Ceritinib) dihydrochloride是有效的抗ALK抑制剂,IC50为0.2 nM,对IGF-1R和InsR的选择性分别为40倍和35倍。 了解更多 -
Entrectinib
Catalog No. A15801 TRK, ROS1, ALK 抑制剂Entrectinib,也称为RXDX-101和NMS-E628,是TrkA,TrkB和TrkC以及ROS1和ALK的小分子抑制剂,具有很高的效力和选择性。 了解更多 -
Brigatinib (AP26113)
Catalog No. A13450 ALK 抑制剂Brigatinib (AP26113)是一种有效的选择性ALK(IC50,0.6 nM)和ROS1(IC50,0.9 nM)抑制剂。它还以较低的效力抑制ROS1,FLT3和FLT3(D835Y)和EGFR的突变体。 了解更多 -
LDN-214117
Catalog No. A16096 -
Duocarmycin GA
Catalog No. A18546 DNA alkylating agentDuocarmycin GA is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin GA can be used against multi-drug resistant cell lines. 了解更多 -
Alectinib Hydrochloride
Catalog No. A18000 ALK inhibitorAlectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. 了解更多 -
Belizatinib
Catalog No. A20919 ALK/TRKA/TRKB/TRKC inhibitorBelizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7?nM for wild-type recombinant ALK kinase. 了解更多 -
Ensartinib hydrochloride
Catalog No. A21719 ALK/MET inhibitorEnsartinib hydrochloride (X-396 hydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. 了解更多 -
Olmutinib (HM61713)
Catalog No. A15976 -
Btk inhibitor 1
Catalog No. A16260 -
LFM-A13
Catalog No. A16261 -
PCI 29732
Catalog No. A16262 -
Poseltinib (HM71224, LY3337641)
Catalog No. A19450 BTK inhibitorPoseltinib, an orally active, selective and irreversible Bruton??s tyrosine kinase (BTK) inhibitor (IC50 =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively. 了解更多 -
CHMFL-BTK-01
Catalog No. A12538 BTK inhibitorCHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. 了解更多 -
Ibrutinib Racemate
Catalog No. A18022 Btk inhibitorIbrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM. 了解更多 -
(R)-Zanubrutinib
Catalog No. A21342 BTK inhibitor(R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor. 了解更多 -
Btk inhibitor 1 (R enantiomer)
Catalog No. A21861 BTK inhibitorBtk inhibitor 1 R enantiomer (Ibrutinib analog) (Compound 14) is a covalent and irreversible Bruton??s tyrosine kinase (BTK) inhibitor and can be used in synthesis of Ibrutinib and ibrutinib-based activity-based probes (ABPs). 了解更多 -
Btk inhibitor 1 R enantiomer hydrochloride
Catalog No. A21865 BTK inhibitorBtk inhibitor 1 R enantiomer hydrochloride (Ibrutinib analog hydrochloride) (Compound 14) is a covalent and irreversible Bruton??s tyrosine kinase (BTK) inhibitor and can be used in synthesis of Ibrutinib and ibrutinib-based activity-based probes (ABPs). 了解更多 -
GDC-0834
Catalog No. A21243